CTLA4 and neoplasm: ICIs can enhance the activity of immune cells and promote the immune system’s attack on tumor cells by inhibiting the immune checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 (PD-1), and programmed cell death ligand 1 (PD-L1).